CUSIP: 30049G104
What is CUSIP 30049G104?
CUSIP 30049G104 identifies EVOK - EVOKE PHARMA INC - COM in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Open recent reporting periods for CUSIP 30049G104:
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2022 Q2 | 0 | $0 | -$987,030 | 0 | |
| 2022 Q1 | 1,997,512 | $987,030 | -$33,393 | $0.49 | 18 |
| 2021 Q4 | 2,045,575 | $1,129,033 | -$2,770,733 | $0.55 | 20 |
| 2021 Q3 | 4,203,343 | $5,463,078 | -$391,583 | $1.30 | 20 |
| 2021 Q2 | 4,504,481 | $6,170,082 | +$218,734 | $1.37 | 19 |
| 2021 Q1 | 4,280,137 | $7,833,000 | +$2,685,816 | $1.83 | 24 |
| 2020 Q4 | 2,613,871 | $6,744,000 | +$1,883,656 | $2.58 | 26 |
| 2020 Q3 | 1,862,922 | $8,738,000 | +$2,219,549 | $4.69 | 25 |
| 2020 Q2 | 1,400,544 | $4,957,000 | +$658,828 | $3.54 | 18 |
| 2020 Q1 | 1,457,285 | $1,689,000 | +$54,501 | $1.16 | 14 |
| 2019 Q4 | 1,453,598 | $2,354,000 | +$13,748 | $1.62 | 15 |
| 2019 Q3 | 1,484,056 | $1,275,000 | +$226,175 | $0.86 | 17 |
| 2019 Q2 | 1,278,062 | $798,000 | -$444,915 | $0.62 | 17 |
| 2019 Q1 | 1,721,798 | $2,554,000 | -$3,965,122 | $1.50 | 21 |
| 2018 Q4 | 3,189,935 | $7,910,000 | -$250,195 | $2.48 | 19 |
| 2018 Q3 | 3,233,329 | $9,639,000 | +$211,874 | $2.98 | 20 |
| 2018 Q2 | 3,168,901 | $7,922,000 | +$2,300,187 | $2.50 | 20 |
| 2018 Q1 | 2,287,040 | $4,756,000 | -$1,210,619 | $2.08 | 20 |
| 2017 Q4 | 2,852,722 | $6,444,000 | +$1,597,569 | $2.26 | 26 |
| 2017 Q3 | 2,102,190 | $7,021,000 | +$495,294 | $3.34 | 21 |
| 2017 Q2 | 1,980,641 | $5,072,000 | +$447,296 | $2.56 | 20 |
| 2017 Q1 | 1,800,168 | $5,580,000 | +$3,895,639 | $3.10 | 22 |
| 2016 Q4 | 585,704 | $1,184,000 | -$140,128 | $2.02 | 14 |
| 2016 Q3 | 633,086 | $1,428,000 | -$810,060 | $2.25 | 12 |
| 2016 Q2 | 446,273 | $3,055,000 | +$417,603 | $6.84 | 13 |
| 2016 Q1 | 386,158 | $1,965,000 | -$113,505 | $5.08 | 11 |
| 2015 Q4 | 418,252 | $1,379,000 | -$297,500 | $3.30 | 14 |
| 2015 Q3 | 510,722 | $1,491,000 | +$135,598 | $2.91 | 9 |
| 2015 Q2 | 459,614 | $2,402,000 | -$148,069 | $5.22 | 12 |
| 2015 Q1 | 472,111 | $3,309,000 | +$480,110 | $7.00 | 11 |
| 2014 Q4 | 404,253 | $2,410,000 | +$35,484 | $5.90 | 11 |
| 2014 Q3 | 404,806 | $2,226,367 | -$402,087 | $5.49 | 11 |
| 2014 Q2 | 409,268 | $3,289,000 | -$24,457 | $8.09 | 9 |
| 2014 Q1 | 411,914 | $3,447,000 | +$2,296,444 | $8.33 | 10 |